Bones are connected by joints, which allow us to move with ease.* Joint damage can cause pain preventing you from doing the things you once loved.* Many conditions lead to joint pain from aging to an untreated sports injury.* A quality joint product may help repair existing tissue damage and also promote stronger joints, less susceptible to future generation.*

Osteosyn Review – How Effective is Osteosyn?

As the owner/sponsor of this e-commerce website, we have the full intention to be compliant with the Federal Trade Commission (FTC) rules about the use of testimonials, endorsements, and overall content in advertising and marketing. Accordingly, we want you as a visitor to understand the instances we get paid to sell all products or services on this site.

Content

The content that appears on this page is presented as a nominative use product overview. The provided information includes product information, overviews, buying guides, and product specifications. All trademarks, registered trademarks and service-marks mentioned on this site are the property of their respective owners. If any content is factually inaccurate please contact us and let us know so that we can address it appropriately. By contributing your product facts helps to better serve our readers and the accuracy of the content.

Our Top Selections Box – Promotional Sales

The table below identified “Our Top Products” does not include all companies or all available products in the market but those that we promote as the owner of and/or resellers of all products listed within it. In full compliance with the FTC guidelines, please assume that any and all links on the table are sales links, and we receive compensation if you click one of these and make a purchase through our website. We are independently owned and the opinions expressed here are our own. All editorial content is written without prejudice or bias, regardless of product sponsor associations.

When purchasing a product, price is the consumer’s primary concern. At present, Osteosyn has 5 products for sale. Osteosyn products range in price from $47.78 to $59.98, and the average price of all the products is about $53.09.

Osteosyn Buying Guide

Looking for chondroitin & glucosamine combination nutritional supplements and chondroitin nutritional supplements products but having no idea? Osteosyn buying guide are here to provide you with a better insight on the quality and performance of the health & household products.

When purchasing a product, price is the consumer’s primary concern. At present, Osteosyn has 5 products for sale. Osteosyn products range in price from $47.78 to $59.98, and the average price of all the products is about $53.09.

We found that most of the Osteosyn products are manufactured by Synutra Pure, Ltd., Synutra Pure, Ltd. The manufacturers provide Osteosyn with a steady supply of products, and they have a good cooperative relationship with each other.

You can purchase Osteosyn products from the Amazon seller Synutra Pure® Joint Care & Wellbeing, over the last 12 months, the seller has received honest feedback from 5 consumers, and the average rating is 5. The store has a good reputation so you can purchase from it with confidence.

How to find more Osteosyn products on FindThisBest?

1. Go back to FindThisBest’s homepage.
2. Type Osteosyn in the search box and hit Enter to see the search results.
3. Find and click the correct Osteosyn to go to the new page.
4. Select the products you want in the Osteosyn buying guide, and take a glance at the prices and features of the products.
5. View the products interest you on Amazon to read the customer reviews and check the ratings. Besides, you can hit the “brand” to find more Osteosyn products.

Frequently Asked Questions (FAQs)

What products does Osteosyn sell?

Osteosyn sells its products and services in the health & household category, mainly including chondroitin & glucosamine combination nutritional supplements and chondroitin nutritional supplements. If you are looking for these products, Osteosyn can be your candidate.

How do I purchase a quality product from Osteosyn?

• Sales quantity. You can check the total sales quantity of the product from Osteosyn.
• Feedback. You can read the reviews offered by other buyers.
• The most important thing is that you should choose the best products according to your actual needs.

How does findthisbest choose the top Osteosyn products?

We analyze millions of Osteosyn products reviews and customer reviews to recommend the best picks for most consumers. We have a professional team with decades of experience to test the products, which can help ensure that we provide our readers with accurate advice and best recommendations.

How many top products do you recommend from a brand?

There are usually 5 to 10 products in a brand buying guide. Osteosyn has a relatively small number of products for sale, only 5, but we analyze all of them in detail and recommended them to our readers.

How can I purchase Osteosyn products via FindThisBest?

1. Go to the Osteosyn page.
2. Select the product you want in the Osteosyn buying guide, and then view the product on Amazon. For example, if you are interested in the top 1 product OSTEOSYN® by Synutra Pure CHONDROITIN 1000+ Pharma. , you can view it on Amazon page.
3. Place your order on Amazon.

Who are the manufacturers of the Osteosyn products?

Most of the Osteosyn products are produced by Synutra Pure, Ltd., Synutra Pure, Ltd. The manufacturers provide Osteosyn with a steady supply of products, and they have a good cooperative relationship with each other.

What is the purpose of your brand guide?

Our mission is to provide you with the most up-to-date and objective information about the Osteosyn products, helping you make more informed buying decisions. We recommend best choices of the products from the Osteosyn brand, helping you make better shopping choices with less time and energy.

We used Arksey and O’Malley’s methods and provide a descriptive analysis of the extent, nature, and distribution of the studies included in the review as well as a narrative, thematic summary of the data collected [20]. For this, we summarized the literature considering study types, location/type of the material and outcomes. On this basis, we analyzed similarities and differences within and in between studies to identify patterns and themes and postulate explanations for findings. Furthermore, we developed an evidence map illustrating the type of evidence, indications and outcomes.

Objectives

The Swiss Federal Office of Public Health delegated us to perform a scoping review to produce a basis for the decision about the feasibility of a full Health Technology Assessment (HTA). This approach is based on the idea to perform a scoping review to assess the feasibility of performing a systematic review [14]. The aim of our contracting authority (Swiss Federal Office of Public Health) was the generation of an evidence base allowing to decide about the feasibility of a full-HTA questioning if hardware removal in patients without medical indication (elective) is effective and safe compared to retaining of hardware covering all parts of the upper and lower extremities.

So far, no systematic review or meta-analysis comparing non-indicated removal of hardware to retaining of hardware in various parts of the extremities exists. However two reviews are known that specialize on syndesmotic screw removal [15, 16]. To generate an overview if there are other body parts of which a full HTA of hardware removal might be useful and to evaluate where and in what extent primary studies are needed we performed a scoping review keeping the surgical site broad. Based on the quality and quantity of the available evidence to answer the central research questions, additional or modified questions can be determined for performing a full HTA.

We performed a scoping review to identify evidence on the elective removal of hardware in asymptomatic patients compared to retaining of the hardware. In addition, we wanted to find out which type of evidence is available.

• According to Dr. Pelletier and his team who recruited 194 patients with primary knee osteoarthritis for a recent study “Chondroitin can slow the long-term progression of knee osteoarthritis while matching the symptom relief of celecoxib” which was presented at American College of Rheumatology 2015 Annual Meeting has found.

Osteosyn reviews

Languages: English | Chinese | Other

Information Not Intended for Consumers

Commnly available osteoarthritis (OA) therapies remain limited with highly invasive arthroscopic surgeries, invasive injections, and pain management meds such as non-steroidal anti-inflammatory drugs (NSAIDs) that are with considerable side effects in long term OA care.

Pharmaceutical grade chondroitin sulfate and chondroitin-glucosamine combination, fortified in potent dosages, are considered symptomatic slow-acting drugs for osteoarthritis (SYSADOA), and are available as safe and effective alternatives to NSAIDs while improving structure and function of articular cartilage. European Pharmacopeia (EP) defines prescription grade chondroitin sulfate at more than 95% assay and consensus studies set effective dosage at 1000 mg or more per serving.

All Osteosyn ® chondroitin and chondroitin-glucosamine combination preparations contain 1000 mg or more chondroitin sulfate per serving, and all active ingredients are traceable for pharma-grade purity compliant to the United States Pharmacopeia (USP) and EP standards.

Incorporating Osteosyn ® chondroitin and chondroitin-glucosamine combination capsules as treatment options enhances orthopedic as well as general practices with orally administered pharmacological therapies for patients not yet needing surgery. This Osteosyn ® Prescriber/Physician Resource provide comprehensive and up-to-date research on OA care and on SYSADOA therapies. The Dispensary links herein to listed Ostesoyn ® preparations are designed to help make adoption easy for you and your practice. Please follow the prescriber link below and register your unique Rx code with which your patients can receive discounts on his orders and you can join our revenue sharing program as you see fit.

Drug Facts

Generic Name: chondroitin sulfate (pharmaceutical/prescription grade, greater than 95% by CPC on dried basis; and USP grade, greater than 90% in assay content); glucosamine hydrochloride (more than 98%)

Brand Name: Osteosyn ® by Synutra Pure: Chondroitin Pure 1000 and Chondroitin 1000+ with glucosamine (both available in low sodium form), and Chondroitin 1200+ with glucosamine

Indications: Symptomatic slow-acting drug for osteoarthritis (SYSADOA)*

Intended Use and Target Population: including FDA Approved Uses and Off-Label Uses: FDA recognizes chondroitin sulfate as a dietary supplement used to provide structure and function support to healthy joint, without making qualified health claim. In European countries and South America, chondtoitin sulfate is considered a symptomatic slow-acting drug for osteoarthritis (SYSADOA). The target population includes early-to-late-stage OA patients before surgical interventions are necessary. In ongoing practice, Osteosyn Chondroitin capsules have been used with discretion as an off-label, non-invasive treatment of OA for patients not needing surgery*.

Dosage Form and Strength (click on drug image or link to go to dispensary of each preparation):

Chondroitin Pure 1000_LS : low sodium, sugar/shellfish free capsules of 500 mgs chondroitin sulfate calcium each, and dosage is 2 capsules per day at 1000mgs calcium chondroitin delivered

Chondroitin Pure 1000 : sugar/shellfish free capsules of 500 mgs chondroitin sulfate each, and dosage is 2 capsules per day at 1000mgs chondroitin delivered

Chondroitin 1000_LS+ with glucosamine : low sodium capsules of 250 mgs chondroitin sulfate calcium each with equal amount of glucosamine hydrochloride, and dosage is 4 capsules per day at 1000mgs of calcium chondroitin delivered

Chondroitin 1000+ with glucosamine : advanced capsules of 250 mgs of chondroitin suflate each with equal amount of glucosamine hydrochloride, and dosage is 4 capsules per day at 1000mgs of chondroitin sulfate delivered

Chondroitin 1200+ with glucosamine : classically formulated capsules of 300 mgs chondroitin suflate each with 375 mgs of glucosamine hydrochloride, and dosage is 4 capsules per day at 1200mgs of chondroitin sulfate delivered

Sign Up as Provider and Get Unique Coupon Code for Patient Discount

Common Adverse Events (Listed in order of decreasing seriousness within each frequency interval): gastrointestinal disorders, rare: nausea, gastrointestinal alterations; general disorders and administration site conditions, very rare: edema, water retention; immune system disorders, very rare: allergic reaction.

Death and Other Serious Adverse Events: None has been reported.

Precautions/Contra-indications: Hypersensitivity to the active ingredient chondroitin sulfate or to any of the excipients; When formulated with glucosamine hydrochloride, cautions include hypersensitivity to glucosamine and shellfish products; Label note: if pregnant, lactating or on prescribed medication, consult your physician before use.

Drug Interactions: None has been reported.

Place in Therapy: With consideration of preponderant clinical evidence on safety and efficacy of chondroitin sulfate as an alternative to NSAIDs in pain management regimes of OA therapy, Osteosyn® Chondroitin capsules have been introduced for use by OA patients in orthopedic practices and various other settings. Patients have responded positively with expected improvement in pain and discomfort, range of motion, increased level of activities, and with no adverse reactions or events reported to date*.

Inclusion Criteria: Patients seeking relief from or treatment for symptoms of degenerative osteoarthritis without needing surgical intervention*.

Dosing and Administration: Oral administration: can be taken before, during or after a meal. Patients with a history of gastric intolerance to medicinal products in general are recommended to take after a meal. No cases of overdosing have been reported. Based on the acute and chronic toxicity results obtained, toxic symptoms are not expected, even after an elevated dose.

Monitoring Parameters: Improvement in joint pain* and discomfort levels; changes in range of motion; changes in activity levels.

Discontinuation Criteria: Lack of appropriate outcomes after using for 6 months, or adverse events.

 

Literature Review and Summary of Findings*:

• Osteoarthritis is the most common form of arthritis and affects more than 27 million Americans, including one quarter of US Veterans according to a 2016 publication by the CDC.

• A recent systematic review of OA therapies classifies chondroitin sulfate, alone or with glucosamine, as a symptomatic and disease modifying therapeutic agent along with other types of current and prospective treatments, including mesenchymal stem cells (MSCs), scaffold-based cartilage regeneration, and potential clinical approaches delivering genes encoding for cartilage growth factors, pro-regenerative mediators, and inflammatory inhibitors specifically to the site of damage. Of the range of therapies reviewed, orally available chondroitin or chondroitin-glucosamine combination have comparable efficacy as non-steroidal anti-inflammatory drugs (NSAIDs) on pain relief and functional improvement in OA patients with moderate-to-severe pain, and proven to be safer than NSAIDs.

• Prescription grade chondroitin (< 95% purity) that meets all the EP and BP criteria for quality has been found in numerous clinical trials to be an effective treatment for osteoarthritis and is considered a symptomatic slow-acting drug for this disease (SYSADOA) in Europe and some other countries.

• According to Dr. Pelletier and his team who recruited 194 patients with primary knee osteoarthritis for a recent study “Chondroitin can slow the long-term progression of knee osteoarthritis while matching the symptom relief of celecoxib” which was presented at American College of Rheumatology 2015 Annual Meeting has found.

• Recent BMJ-published meta-analysis of diverse OA treatments not including joint arthroplasty reported overall treatment effect and the proportion attributable to contextual effect, commonly known as placebo effect) of a range of OA therapies including NSAIDs, chondroitin, paracetamol, inter-articular corticosteroid, joint lavage, etc. Compared in oral pain treatment options, NSAID showed an overall treatment effect size (95% CI) or ES of 1.11 and a proportion attributable to contextual effect (PCE) of 0.70 while chondroitin was reported with a 1.29 ES and a PCE of 0.68. When considering documented side effects and reported adverse events associated with NSAIDs, pharmaceutical level chondroitin preparation appears to be a clear alternative to NSAIDs in OA therapies.

• Due to its classification as a dietary supplement, most companies in the US do not meet the prescription purity and other quality parameters outlined in the EP and BP.

• Most chondroitin products on the market contain glucosamine derived from shellfish which poses a problem to people who suffer from shellfish allergies.

• Only two companies in the US manufacture a chondroitin product that meets the EP of which only one offers a chondroitin only format which takes away the allergen and potential diabetes risk that glucosamine products have.

• Clinical studies have not identified any significant side effects or overdoses of chondroitin sulfate, which suggest its long-term safety. The Task Force of the European League Against Rheumatism (EULAR) committee recently granted chondroitin sulfate a level of toxicity of 6 in a 0-100 scale, confirming it is one of the safest drugs for osteoarthritis. Moreover, its safety is supported by an absence of drug-drug (chondroitin sulfate is not metabolized by cytochrome P450), and the lack of safe alternatives for patients multi-medicated for osteoarthritis and other accompanying diseases, e.g. diabetes, hypertension, hyperlipidemia, etc.

• The large scale 4-year GAIT study reported in 2006 that glucosamine and chondroitin sulfate did not provide significant relief from arthritis pain in all people. However, a smaller subgroup of study participants with moderate-to-severe pain showed significant relief with the combined supplements.

• The Cochrane Review Published on January 28th, 2015, which consisted of 43 studies with 9,110 people, concluded:

√ Chondroitin may improve pain slightly in the short-term (less than 6 months);

√ Chondroitin improves knee pain by 20% in slightly more people;

√ Chondroitin probably improves quality of life slightly as measured by Lequesne’s index (combined measure of pain, function, and disability);

√ Chondroitin has little or no difference in adverse and serious adverse events versus other agents; and

√ Chondroitin slightly slows down the narrowing of joint space on X-rays of the affected joint.

• A pharmacoeconomic analysis by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) produced a consensus statement that provides “evidence in support of pharmacological interventions “with symptomatic slow-acting drugs for osteoarthritis (SYSADOAs, including chondroitin sulfate), in terms of management of OA pain and function, avoidance of adverse events, disease-modifying effects and long-term outcomes,” including delay of total joint replacement surgery, and pharmacoeconomic factors such as reduction in healthcare resource utilization.

Visit www.osteosyn.com/research.html to review and download full text of select studies listed below:

M.H. Li, R. Xiao, J.B. Li, Q. Zhu. Regenerative approaches for cartilage repair in the treatment of osteoarthritis. Osteoarthritis Research Society International (OARSI), Osteoarthritis and Cartilage 25 (2017) 1577-1587.

Zou K, Wong J, Abdullah N, Chen X, Smith T, Doherty M, Zhang W. Examination of overall treatment effect and the proportion attributable to contextual effect in osteoarthritis: meta-analysis of randomized controlled trials. Group BMJ, Oct 26, 2016 Bishnoi M, Jain A, Hurkat P, Jain SK, Chondroitin sulphate: a focus on osteoarthritis Glycoconjugate Journal 19 May 2016 pp 1-13.

Mantovani V, Maccari F, Volpi N. Chondroitin Sulfate and Glucosamine as Disease Modifying Anti-Osteoarthritis Drugs (DMOADs) Curr Med Chem. 2016; 23(11):1139-51.

Raynauld JP, Pelletier JP, Abram F, Delorme P, Martel-Pelletier J. Long-term effects of glucosamine/chondroitin sulfate on the progression of structural changes in knee osteoarthritis: 6-year follow-up data from the osteoarthritis initiative. Arthritis Care Res (Hoboken). 2016 Feb 16. DOI: 10.1002/acr. 22866.

Hochberg MC, Martel-Pelletier J, Monfort J, Möller I, Castillo JR, Arden N, Berenbaum F, Blanco FJ, Conaghan PG, Doménech G, Henrotin Y, Pap T, Richette P, Sawitzke A, du Souich P, Pelletier JP; MOVES Investigation Group. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis. 2016 Jan;75(1):37-44.

Provenza JR, Shinjo SK, Silva JM, Peron CR, Rocha FA. Combined glucosamine and chondroitin sulfate, once or three times daily, provides clinically relevant analgesia in knee osteoarthritis. Clin Rheumatol. 2015 Aug;34(8):1455-62.

Singh JA, Noorbaloochi S, MacDonald R, Maxwell LJ. Chondroitin for osteoarthritis. Cochrane Database of Systematic Reviews 2015, Issue 1. Art. No.: CD005614. DOI: 10.1002/14651858.CD005614.pub2.

Bruyere O, Cooper C, Pelletier JP, Maheu E, Rannou F, Branco J, Brandi M, Kanis J, Altman R, Hochberg M, Martel-Pelletier J, Reginster J. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis–From evidence-based medicine to the real-life setting. Seminars in Arthritis and Rheumatism, Elsevier, 2015.

Purvis L, Carter E, Morin P Impact of the Medicare Hospital Readmission Reduction Program on Hospital Readmissions Following Joint Replacement Surgery, AARP Public Policy Institute, Oct 2015 Martel-Pelletier J, Farran A, Montell E, Vergés J and Pelletier J, Discrepancies in Composition and Biological Effects of Different Formulations of Chondroitin Sulfate, Molecules 2015, 20, 4277-4289; doi:10.3390/molecules 20034277.

Zhang W, Giancaspro G, Adams K, Neal-Kababick J, Hildreth J, Li A, Roman M, Betz J Electrophoretic Separation of Alginic Sodium Diester and Sodium Hexametaphosphate in Chondroitin Sulfate that Interfere with the Cetylpyridinium Chloride Titration Assay, Journal of AOAC International Vol. 97, No. 6, 2014.

Fardellone P, Zaim M, Saurel AS, Maheu E. Comparative efficacy and safety study of two chondroitin sulfate preparations from different origin (avian and bovine) in symptomatic osteoarthritis of the knee. Open Rheumatol J. 2013; 7:1-12.

Schneider H, Maheu E, Cucherat M. Symptom-modifying effect of chondroitin sulfate in knee osteoarthritis: a meta-analysis of randomized placebo-controlled trials performed with structum® Open Rheumatol J. 2012; 6:183–9. Pavelka K, Coste P, Géher P, Krejci G. Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clin Rheumatol. 2010; 29:659–70.

Jordan KM; Recommendations Arden NK. EULAR (2003), “an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)”. Ann Rheum Dis 62 (12): 1145–1155. doi:10.1136/ard. 2003.01174.

Volpi N. Oral bioavailability of chondroitin sulfate (Condrosulf ®) and its constituents in healthy male volunteers, Osteoarthritis and Cartilage (2002) 10, 768–777.

Bourgeois P, Chales G, Dehais J, Delcambre B, Kuntz JL, Rozenberg S. Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 x 400 mg/day vs placebo. Osteoarthritis Cartilage. 1998; 6 (Suppl A):25–30.

Bucsi L, Poor G. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SySADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage. 1998; 6 (Suppl A):31–6.

Morreale P, Manopulo R, Galati M, Boccanera L, Saponati G, Bocchi L. Comparison of the anti-inflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol. 1996; 23:1385–91.

Thilo G, A Study of 35 Cases of Arthrosis Treated with Chondroitine Sulphuric Acid, Schweiz. Rundschau Med. (PRAXIS) 66 (1977).

Register to Get Unique Provider Code for Patient Discount

Note to Prescriber:

In WeChat, scan or long-press this QR code ↓ to enter, save, or share this Prescriber/Physician Resource Page